The intersection of community-based sports and clinical health advocacy has emerged as a critical pillar in the modern landscape of cancer survivorship. For Tori Ashman, a mother and athlete, the journey through a Stage 1B breast cancer diagnosis served as a profound case study in how social "sisterhoods" and specialized support organizations can fundamentally alter the trajectory of a patient’s recovery. By bridging the gap between the volleyball court—specifically the Mamanet league—and the oncology clinic, Ashman’s experience highlights the vital importance of early detection, genetic awareness, and the psychological impact of communal support.
Main Facts: A Convergence of Sport and Support
In early 2023, Tori Ashman was diagnosed with Stage 1B invasive ductal carcinoma. While the diagnosis was a turning point, the foundation for her resilience had been laid years prior through two distinct entities: Mamanet and Sharsheret.
Mamanet, an international mothers’ cachibol (newcomb ball) league, provided the social framework that Ashman credits with maintaining her mental fortitude. Founded on the principles of community, physical activity, and mutual aid among mothers, the league transformed from a recreational outlet into a front-line support system.
Simultaneously, Sharsheret—a national non-profit organization dedicated to supporting Jewish women and families facing breast and ovarian cancer—provided the clinical and emotional scaffolding necessary to navigate the complexities of the healthcare system. Together, these organizations formed a "safety net" that addressed both the physical realities of cancer treatment and the often-overlooked psychosocial needs of the patient and her family.
Chronology: From Routine Screening to Diagnostic Reality
The path to Ashman’s diagnosis was not a singular event but rather a multi-year odyssey of proactive health management. Her experience underscores the "diagnostic treadmill" that many women at high risk must endure.
The Initial Screening (Age 40):
Following standard medical guidelines, Ashman scheduled her first mammogram at age 40. This initial screening led to an immediate call-back for additional imaging—a moment Ashman recalls as the beginning of her heightened awareness regarding breast health. While that specific instance resulted in a lumpectomy rather than a cancer diagnosis, it established a pattern of rigorous surveillance.
The Cycle of Surveillance:
For several years, Ashman underwent a "subscription box" of medical procedures: annual mammograms, follow-up ultrasounds, and repeated biopsies. This period of "watchful waiting" is a common reality for women with dense breast tissue or a family history of the disease, creating a state of perpetual medical anxiety.
The February 2023 Diagnosis:
The cycle of biopsies eventually culminated in a positive diagnosis of Stage 1B invasive ductal carcinoma in February 2023. Unlike her previous scares, this required an intensive treatment plan. It was at this juncture that the theoretical support of Sharsheret became a practical lifeline.
Treatment and Recovery:
Throughout her treatment, Ashman’s Mamanet team pivoted from teammates to caregivers. The league organized "tribute games" and provided a steady stream of emotional and logistical support. By late 2024 and early 2025, Ashman transitioned into the role of an advocate, utilizing her story to emphasize the efficacy of early detection.
Supporting Data: The Clinical Significance of Early Detection
Ashman’s survival and current health status are directly attributable to the timing of her diagnosis. Her case serves as a living testimonial to the statistics provided by the American Cancer Society and the National Breast Cancer Foundation.
- Survival Rates: When breast cancer is detected early and remains localized, the five-year relative survival rate is approximately 99%. Ashman’s Stage 1B diagnosis allowed for an intervention before the cancer could metastasize to distant organs, where survival rates drop significantly.
- The Power of Mammography: Clinical data suggests that mammography can identify breast abnormalities up to three years before they can be felt as a lump. Ashman’s adherence to her screening schedule was the primary factor in catching the carcinoma at an actionable stage.
- The Ashkenazi Jewish Risk Factor: Sharsheret’s involvement is particularly relevant given the genetic context. Women of Ashkenazi Jewish descent have a 1 in 40 chance of carrying a BRCA gene mutation—nearly ten times higher than the general population. While Ashman’s specific genetic status is a private clinical matter, the role of Sharsheret in providing genetic counseling is a critical data-driven response to this community-specific risk.
Official Responses: The Role of Sharsheret and Mamanet
Representatives from the organizations involved emphasize that Ashman’s story is emblematic of their broader missions.
Sharsheret’s Holistic Approach:
Sharsheret (Hebrew for "chain") operates on the philosophy that a cancer diagnosis affects the entire family unit. Their "Busy Box" program, which Ashman utilized, provides age-appropriate resources for children to help them understand a parent’s illness. "We don’t just answer questions; we hold hands through every scan and every sleepless night," the organization states. Their peer support network connects patients with "Linkers"—women of similar ages and diagnoses—to provide nuanced, experiential advice that clinical staff may not be able to offer.
Mamanet’s Community Philosophy:
Mamanet advocates argue that the league is "community in motion." Beyond the physical benefits of the sport, the league creates a pre-existing infrastructure of support. When a member falls ill, the "team" mentality naturally shifts toward communal care. For Ashman, this meant her teammates dedicated games to her recovery and maintained constant contact, mitigating the isolation often felt during chemotherapy and surgical recovery.
Implications: The Future of Patient-Centric Advocacy
The narrative of Tori Ashman offers several broader implications for the fields of oncology, social work, and public health.
1. The "Social Prescribing" Model:
Ashman’s experience lends weight to the concept of "social prescribing," where healthcare providers recognize the clinical value of community involvement. Belonging to a group like Mamanet can reduce cortisol levels and improve mental health outcomes, which are known to influence physical recovery rates in cancer patients.
2. Destigmatizing the "Subscription" to Screening:
By describing her annual biopsies as a "subscription box," Ashman reframes a frightening medical process as a manageable, albeit tedious, part of life. This perspective is vital for public health messaging, encouraging women to persist with screenings even when they face "false positives" or repeated biopsies.
3. The Multi-Generational Impact:
The mention of Ashman’s sister, who is battling Stage 4 breast cancer, highlights the familial burden of the disease. It underscores the necessity of organizations like Sharsheret that provide specialized support for families dealing with multiple diagnoses, addressing the unique psychological strain of being both a patient and a caregiver.
4. Normalcy as a Clinical Goal:
Perhaps the most significant implication is the shift in how "success" is defined in cancer treatment. Ashman notes that early detection "saves normalcy." The ability to continue making dinner, attending sports practice, and participating in community life is not just a byproduct of survival—it is a primary goal of modern oncology.
Conclusion: A Call to Action
Tori Ashman’s journey from the Mamanet court to the oncology clinic serves as a powerful reminder that the fight against breast cancer is rarely won in isolation. It is a collaborative effort involving proactive patients, diligent clinicians, and a robust support network of peers.
The overarching message of her experience is one of urgent advocacy. "Schedule your mammogram. Don’t let fear or busyness stop you," Ashman insists. As the medical community continues to refine treatments for invasive ductal carcinoma, the human element—the "sisterhood" of the court and the "chain" of Sharsheret—remains the most potent tool in ensuring that survivors do not just live, but thrive.
For those currently navigating a diagnosis, Ashman’s story stands as evidence that while cancer may shake one’s foundation, a strong enough community can hold the structure together. The integration of clinical excellence and communal love represents the gold standard for the future of cancer care, ensuring that no patient has to "play this game alone."
About the Author
